Find a Doctor

Nitya P. Raj
NR
Areas of Expertise

Nitya P. Raj

Memorial Solid Tumor Group
Oncology, Hematology, Internal Medicine
Female
Practicing approx. 11 years

Bio

Nitya Raj is an Oncologist and an Internal Medicine specialist in New York, New York. She has been an author on 22 peer reviewed articles and participated in 8 clinical trials in the past 15 years. She is licensed to treat patients in NY.

Areas of Expertise

Contact

1275 York Ave
New York, NY 10065, US

212-639-2000

Latest Advances

Latest Advance
Study
  • Condition: Metastatic Pancreatic Neuroendocrine Tumor
  • Journal: Current treatment options in oncology
  • Treatment Used: Various
  • Number of Patients: 0
  • Published —
This article described various systemic therapies used to treat metastatic pancreatic neuroendocrine tumors
Latest Advance
Study
  • Condition: Metastatic Pancreatic Neuroendocrine Tumor
  • Journal: PloS one
  • Treatment Used: RAF and MEK inhibitors
  • Number of Patients: 80
  • Published —
The study researched the use of RAF and MEK inhibitors in treating metastatic pancreatic neuroendocrine tumor.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Other, Drug
  • Participants: 76
  • Start Date: November 2, 2020
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Drug
  • Participants: 395
  • Start Date: July 18, 2018
Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)

All Publications
View All

Publication
Conference
  • Sponsor: Endocrine Society (ENDO)
  • Event Name: Endocrine Society Annual Meeting 2020
  • Published —
Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results- a Case Report
Publication
Study
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Published —
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx).

Contact

1275 York Ave
New York, NY 10065, US

212-639-2000

Affiliations

  • Memorial Hospital For Cancer And Allied Diseases

Credentials

  • Graduate InstitutionUniversity Of Michigan Medical School
    2010
  • Licenses
    Internal Medicine in NY
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.